References
- Papamichael K, Afif W, Drobne D, et al. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022;7:171–185.
- Zhang Y, Jiang W, Xu C, et al. The impact of proactive versus reactive drug monitoring of infliximab on treatment outcomes in patients with crohn’s disease. Scand J Gastroenterol. 2024;59(3):269–279.
- Desai DC, Dherai AJ, Strik A, et al. Personalized dosing of infliximab in patients with inflammatory bowel disease using a bayesian approach: a next step in therapeutic drug monitoring. J Clin Pharmacol. 2023;63(4):480–489.
- Dubinsky MC, Mendiolaza ML, Phan BL, et al. Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity. Inflamm Bowel Dis. 2022;28(9):1375–1385. doi: 10.1093/ibd/izab285.
- Strik AS, Löwenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56:145–154.
- Papamichael K, Cheifetz AS. Therapeutic drug monitoring in patients on biologics: lessons from gastroenterology. Curr Opin Rheumatol. 2020;32(4):371–379. doi: 10.1097/BOR.0000000000000713.
- Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031.
- Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779–2789.